To improve quality of life in the long term for patients living with pain, you need innovations. And that’s exactly what we work on every day. With more than 20% of our annual revenue, our investment in research and development is way above the industry average. We are constantly striving to create new and improved products – products which are effective against symptoms that have previously been difficult to treat, and which cause fewer side effects.
|<40||We have worked in the pain area for more than 40 years so we have the experience and dedication to develop new medicines for pain patients|
|~240||Our 2015 R&D budget to invest into new projects is about € 240 mn|
|~600||About 600 colleagues work across all aspects of R&D that are required to take a compound from idea to a medicine|
|330||We have filed around 330 patent applications filed over the last ten years protecting our novel ideas|
Our strong track record in successful pain medication began with the launch of Tramal® in 1977, and continues to this day with our latest products. These include therapeutic agents with innovative mechanisms of action, as well as novel dosage forms for a broad range of pain conditions.